.png)
.png)
Epidemiologist- CMV
Moderna, Inc.
Disclosure(s): Moderna, Inc.: Salary, Stocks/Bonds
Currently, John is Director, Lead Epidemiologist for Moderna’s mRNA-1647 CMV vaccine candidate. John supports all epidemiology related activities for the CMV development program including addressing evidence gaps in the field, highlighting the direct and indirect benefits of CMV vaccination, and supporting federal and state discussions on the importance of newborn screening.
Prior to working at Moderna, John worked at GSK supporting both Vaccines and Pharma divisions. Within GSK Vaccines John was a lead epidemiologist on Shingrix, a preventative vaccine against herpes zoster (aka shingles) in older adults. He led multiple post-marketing commitment studies in the US, Japan and China. He played a critical role in helping obtain license approval for Shingrix in China in 2019. Within GSK Pharma, John was lead epidemiologist within the immuno-oncology group supporting an early phase asset targeting colorectal cancer, and belantamab mafodotin, a treatment for patients with relapsed or refractory multiple myeloma who have had at least 4 prior lines of therapy.
Prior to joining GSK, John worked at the Los Angeles County Department of Public Health as a researcher managing ongoing molecular epidemiology studies of respiratory tract pathogens and antibiotic resistant organisms. He also concurrently served as an adjunct faculty teaching courses in Epidemiology and Public Health at the California State University, Dominguez Hills, UCLA Fielding School of Public Health and UCLA Nursing School.
John earned his Master’s degree in Experimental and Molecular Pathology from the University of Southern California. He received his PhD from the UCLA Fielding School of Public Health.
John works remotely from Potomac, Maryland and enjoys daily runs, weight training, and makes an amazing pumpkin pie.